October 14, 2026 edition, released October 15, 2026. BioNTech's BNT113 missed progression-free survival in its pivotal head and neck cancer trial, leaving overall survival as the remaining path to a positive result. Roche licensed Rona Therapeutics' undisclosed ALK7-targeting RNAi obesity candidate—a fat-cell approach with most potential deal value contingent on milestones. Johnson & Johnson raised full-year guidance as newer medicines offset Stelara erosion; the roundup also covers FDA review of FYB206, a proposed Keytruda (pembrolizumab) biosimilar, Syndax ending axatilimab in IPF, 84-week Pasatru (garetosmab) data in FOP, and Tremfya (guselkumab) analyses in Crohn's perianal fistulas.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →